Jefferies initiates Abivax stock coverage with buy rating on UC drug

📌 Key Takeaways

• Jefferies initiates coverage of Abivax stock with a buy rating.
• The rating is based on the company's drug for ulcerative colitis (UC).
• This suggests confidence in the drug's potential and Abivax's market prospects.
• The coverage may influence investor interest and stock performance.

🏷️ Themes

Stock Analysis, Pharmaceuticals

Entity Intersection Graph

No entity connections available yet for this article.

Source

investing.com